Formosa Pharmaceuticals, Inc. (TPE:6838)

Formosa Pharmaceuticals Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	273.17	241.79	425.79	384.71	267.34	208.92
Short-Term Investments	1,110	1,200	1,220	831.41	153.55	-
Cash & Short-Term Investments	1,383	1,442	1,646	1,216	420.89	208.92
Cash Growth	-13.27%	-12.39%	35.33%	188.94%	101.46%	398.99%
Other Receivables	27.36	25.7	51.66	46.44	14.72	13.88
Receivables	53.86	25.7	51.66	46.44	14.72	13.88
Inventory	4.77	4.17	2.89	-	-	-
Prepaid Expenses	43.94	44.12	26.94	25.34	20.57	11.66
Other Current Assets	1.43	0.16	0.52	0.44	0.13	0.04
Total Current Assets	1,487	1,516	1,728	1,288	456.31	234.5
Property, Plant & Equipment	40.96	43.56	29.89	34.36	10.18	8.19
Long-Term Investments	1.52	1.54	5.15	27.26	-	-
Goodwill	30.54	30.54	30.54	30.54	30.54	30.54
Other Intangible Assets	421.31	431.77	311.85	345.64	380.2	414.83
Other Long-Term Assets	48.94	47.89	7.05	0.65	0.67	0.65
Total Assets	2,030	2,071	2,112	1,727	877.91	688.72

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	2.61	0.77	-	-	-	-
Accrued Expenses	62.28	89.74	128.36	86.67	66.09	7.17
Current Portion of Leases	5.86	6.57	5.5	5.5	2.5	2.76
Current Unearned Revenue	3.52	21.29	4.51	71.33	-	-
Other Current Liabilities	55.01	48.04	59.59	94.48	0.98	9.37
Total Current Liabilities	129.27	166.42	197.95	257.98	69.57	19.3
Long-Term Leases	19.46	20.41	20.3	24.29	4.41	0.42
Long-Term Unearned Revenue	22.24	16.76	23.48	1.66	-	-
Long-Term Deferred Tax Liabilities	3.33	3.46	3.95	4.45	4.94	5.43
Other Long-Term Liabilities	414.34	407.02	318.02	297.84	331.6	270.33
Total Liabilities	588.64	614.06	563.7	586.21	410.51	295.48

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	1,510	1,510	1,510	1,341	1,136	988.32
Additional Paid-In Capital	2,279	2,279	2,279	1,780	978.52	620.49
Retained Earnings	-2,252	-2,237	-2,153	-1,952	-1,630	-1,202
Comprehensive Income & Other	-95.93	-95.74	-87.59	-29.91	-18.14	-14.53
Total Common Equity	1,441	1,457	1,548	1,140	466.83	392.74
Minority Interest	0.56	0.55	0.59	0.54	0.57	0.49
Shareholders' Equity	1,442	1,457	1,549	1,141	467.4	393.23
Total Liabilities & Equity	2,030	2,071	2,112	1,727	877.91	688.72

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	25.32	26.99	25.8	29.79	6.9	3.18
Net Cash (Debt)	1,358	1,415	1,620	1,186	413.99	205.74
Net Cash Growth	-13.53%	-12.67%	36.55%	186.56%	101.22%	476.99%
Net Cash Per Share	8.99	9.37	11.50	9.56	3.94	2.22
Filing Date Shares Outstanding	150.98	150.98	150.98	134.14	113.64	98.83
Total Common Shares Outstanding	150.98	150.98	150.98	134.14	113.64	98.83
Working Capital	1,358	1,350	1,530	1,030	386.75	215.2
Book Value Per Share	9.55	9.65	10.25	8.50	4.11	3.97
Tangible Book Value	989.39	994.31	1,206	763.85	56.09	-52.64
Tangible Book Value Per Share	6.55	6.59	7.99	5.69	0.49	-0.53
Machinery	23.84	23.76	8.14	7.38	7.44	7.44
Leasehold Improvements	0.7	0.7	0.7	0.45	1.54	1.54

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 25, 2026

Data Sources Report a data error